A nasal preparation and its application

By optimizing the ingredient ratio of the nasal formulation, the stability and safety issues of emesitine nasal formulations in the prior art have been resolved, achieving effective delivery of emesitine into the nasal cavity and significant therapeutic effects on allergic rhinitis.

CN120884540BActive Publication Date: 2026-11-17JIANGSU DEMAI PHARMACEUTICAL CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202511334905.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-09-17
Publication Date
2026-11-17
Estimated Expiration
2045-09-17

AI Technical Summary

Technical Problem

There is a lack of stable, safe and effective nasal liquid formulations of emestin in the current technology. Directly applying the eye drop formulation to the nasal cavity may lead to insufficient efficacy or safety issues, and there is a lack of clear control over the spray particle size.

Method used

By optimizing the ratio of thickeners, osmotic pressure regulators, metal ion chelators, and pH adjusters, the retention and local bioavailability of emestin during nasal delivery are improved, ensuring the physicochemical stability of the formulation. The droplet size is controlled through a specific nasal spray device, making it suitable for a wide range of people, including children.

Benefits of technology

This study achieved stability and safety in emestin nasal formulations, improved drug distribution and absorption efficiency on the nasal mucosa, reduced drug loss and systemic absorption, and significantly relieved symptoms of allergic rhinitis and other diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure SMS_2
    Figure SMS_2
Patent Text Reader

Abstract

This application relates to a nasal preparation and its application, wherein the active ingredient is only emestin or a pharmaceutically acceptable salt thereof.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This application relates to the field of biomedicine, specifically to a nasal preparation and its application. Background Technology

[0002] Seasonal allergic rhinitis (SAR) is a common allergic disease, mainly characterized by nasal congestion, runny nose, sneezing, and nasal itching, significantly impacting patients' quality of life. H1 receptor antagonists are first-line drugs for treating this condition. Among them, emedastine difumarate, a second-generation H1 receptor antagonist, has good antihistamine effects and low central nervous system depressant side effects, and has been widely used to treat allergic conjunctivitis and is commercially available as eye drops.

[0003] However, research and development on emesitine for nasal delivery remains limited. In the existing technology, most disclosed emesitine formulations are eye drops, and very few documents or patents describe in detail its composition, physicochemical properties, atomization characteristics, and impact on efficacy and safety as a nasal liquid formulation. Because the structure and barrier properties of the nasal mucosa differ significantly from those of the eye, directly applying eye drop formulations to nasal preparations may lead to insufficient efficacy or safety issues.

[0004] Currently, there is no literature that clearly reports a liquid nasal spray formulation containing only emestin as the active ingredient, and which has clear spray particle size control, good physicochemical properties, and stability. Summary of the Invention

[0005] This application provides a novel nasal liquid formulation of emesostine. By optimizing the ratio of thickener, osmotic pressure regulator, metal ion chelating agent, and pH adjuster, the retention and local bioavailability of emesostine during nasal delivery are improved. More importantly, this formulation exhibits good physicochemical stability while balancing local efficacy and safety. Specifically, the formulation provided in this application has one or more of the following advantages:

[0006] 1. Good stability: The synergistic effect of the metal ion complexing agent and the buffer system can inhibit the degradation of emesitin in the aqueous environment, ensuring the stability of the physicochemical properties and efficacy of the formulation during storage;

[0007] 2. High safety: The formula does not contain any additives that may cause irritation. Through the combination of thickeners and a specific nasal spray device, the droplet size is controlled within a reasonable range to avoid inhalation risks. It is suitable for a wide range of people, including children.

[0008] 3. Significant therapeutic effect: It improves the distribution and absorption efficiency of drugs on the nasal mucosa surface, and enhances the relief effect on symptoms of diseases such as allergic rhinitis;

[0009] 4. Excellent local delivery performance: It increases the residence time of the drug on the nasal mucosa, reduces drug loss and systemic absorption, and is conducive to exerting the local antihistamine effect of emesitine.

[0010] On the one hand, this application provides a nasal preparation containing only emestin or a pharmaceutically acceptable salt thereof as its active ingredient.

[0011] In some embodiments, the pharmaceutically acceptable salt of emesine includes emesine fumarate.

[0012] In some embodiments, the content of the active ingredient in the nasal preparation is 0.01% to 5% (w / v%).

[0013] In some embodiments, the nasal preparation has at least one of the following physicochemical properties:

[0014] a) pH value is 3.0~8.0;

[0015] b) Viscosity is 0.5~5.0 mPa·s;

[0016] c) The osmolar concentration is 260~350 mOsmol / kg.

[0017] In some embodiments, the nasal formulation comprises a pH adjuster, a metal ion complexing agent, an osmotic pressure regulator, and a thickener.

[0018] In some embodiments, the pH adjuster is selected from citric acid, sodium citrate, sodium hydroxide, and / or hydrochloric acid.

[0019] In some embodiments, the citric acid content is 0.001% to 2% (w / v%), and the sodium citrate content is 0.001% to 1% (w / v%).

[0020] In some embodiments, the metal ion chelating agent in the nasal preparation is disodium edetate.

[0021] In some embodiments, the content of disodium edetate is 0.001% to 0.1% (w / v%).

[0022] In some embodiments, the osmotic pressure regulator in the nasal formulation is selected from sodium chloride, propylene glycol, glycerin, glucose, or combinations thereof.

[0023] In some embodiments, the sodium chloride content is 0.05% to 2% (w / v%).

[0024] In some embodiments, the content of propylene glycol, glycerol, or glucose is 0.5% to 10% (w / v%).

[0025] In some embodiments, the thickener in the nasal formulation is selected from sucrose, pectin, microcrystalline cellulose sodium carboxymethyl cellulose co-processed product, sodium carboxymethyl cellulose, hydroxypropyl methylcellulose, povidone, or combinations thereof.

[0026] In some embodiments, the viscosity of the 2% aqueous solution of hydroxypropyl methylcellulose is about 1000 to 10000 mPa·s.

[0027] In some embodiments, the content of hydroxypropyl methylcellulose is 0.005% to 5% (w / v%).

[0028] In some embodiments, the content of the povidone is 0.01% to 2% (w / v%).

[0029] In some embodiments, the nasal preparation comprises the following ingredients: emesartan fumarate, in a content of 0.01% to 5% (w / v%); citric acid, in a content of 0.001% to 2% (w / v%); sodium citrate, in a content of 0.001% to 1% (w / v%); disodium edetate, in a content of 0.001% to 0.1% (w / v%); sodium chloride, in a content of 0.05% to 2% (w / v%); hydroxypropyl methylcellulose, in a content of 0.005% to 5% (w / v%); and the pH is adjusted to 3.0 to 8.0 by sodium hydroxide.

[0030] In some embodiments, the nasal formulation comprises the following ingredients: 0.4% (w / v%) emestin fumarate, 0.048% (w / v%) citric acid, 0.008% (w / v%) sodium citrate, 0.01% (w / v%) disodium edetate, 0.75% (w / v%) sodium chloride, 0.1% (w / v%) hydroxypropyl methylcellulose, and pH adjusted to 5.5 by sodium hydroxide.

[0031] In some embodiments, the nasal preparation also includes a moisturizer.

[0032] In some embodiments, the moisturizer is selected from sorbitol and / or mannitol.

[0033] In some embodiments, the content of sorbitol or mannitol is 0.5% to 10% (w / v%).

[0034] In some embodiments, the nasal formulation further comprises an absorption enhancer.

[0035] In some embodiments, the absorption enhancer is selected from fatty acids, bile salts, phospholipids, polyethylene glycol and its derivatives, alkyl glycosides, cyclodextrin and its derivatives, or combinations thereof.

[0036] In some embodiments, the absorption enhancer is dodecyl maltodextrin, and the content of dodecyl maltodextrin is 0.01% (w / v%).

[0037] In some embodiments, the nasal preparation is a sterile preparation.

[0038] In some embodiments, the nasal preparation also contains an antibacterial agent.

[0039] In some embodiments, the antibacterial agent is selected from quaternary ammonium salts, alcohols, organic acids and their salts, parabens, or combinations thereof.

[0040] In some embodiments, the antibacterial agents in the nasal preparation are benzalkonium chloride, benzyl alcohol, phenylethanol, potassium sorbate, sodium benzoate, or combinations thereof.

[0041] In some embodiments, the antibacterial agent is benzalkonium chloride, and the content of benzalkonium chloride is 0.001%~0.5% (w / v%).

[0042] In some embodiments, the dosage form of the nasal preparation is selected from one or more of the following: spray, aerosol, and nasal drops.

[0043] In some embodiments, the droplet size distribution of the spray agent, when measured at a spray distance of 3 cm or 6 cm, has the following characteristics: D50 particle size is 30~150 μm, the proportion of droplets with a particle size less than 10 μm is less than 5%, and the droplet size distribution span is less than 3.0.

[0044] In some embodiments, the nasal preparation is an aqueous composition.

[0045] On the other hand, this application provides a method for treating allergic rhinitis and / or conjunctivitis, comprising administering an effective amount of the nasal preparation described in this application to a subject.

[0046] On the other hand, this application provides the use of the nasal preparation described in this application in the preparation of a medicament for treating allergic rhinitis and / or conjunctivitis.

[0047] On the other hand, this application provides the use of the nasal preparation described in this application in the treatment of allergic rhinitis and / or conjunctivitis.

[0048] In some embodiments, the allergic rhinitis includes seasonal allergic rhinitis and perennial allergic rhinitis.

[0049] On the other hand, this application provides a method for preparing the nasal formulation described in this application, which includes dissolving emestin or a pharmaceutically acceptable salt thereof, and the remaining components of the nasal formulation, in water capable of achieving a desired concentration range in the resulting solution.

[0050] On the other hand, this application provides a packaging device for a nasal preparation described in this application, which includes a nasal spray bottle provided with a nozzle and a pump device for controlling the dosage.

[0051] In some embodiments, the packaging device has a bacterial barrier function.

[0052] Other aspects and advantages of this application will readily be apparent to those skilled in the art from the detailed description below. Only exemplary embodiments of this application are shown and described in the following detailed description. As will be appreciated by those skilled in the art, the content of this application enables them to make modifications to the disclosed specific embodiments without departing from the spirit and scope of the invention to which this application pertains. Accordingly, the descriptions in the accompanying drawings and specification of this application are merely exemplary and not restrictive. Attached Figure Description

[0053] The specific features of the invention involved in this application are shown in the appended claims. The features and advantages of the invention can be better understood by referring to the exemplary embodiments and drawings described in detail below. A brief description of the drawings is as follows:

[0054] Figure 1A-Figure 1B The graph shows the average blood drug concentrations in Beagle dogs after nasal administration of the emesitin nasal formulation described in this application and oral administration of emesitin fumarate extended-release capsules. Figure 1A ) and the semi-logarithmic graph of blood drug concentration ( Figure 1B (See figure 1). Group 1 in the figure is the group receiving emesitine nasal spray, and group 2 in the figure is the group receiving emesitine fumarate sustained-release capsules. Detailed Implementation

[0055] The following specific embodiments illustrate the implementation of the invention. Those skilled in the art can easily understand other advantages and effects of the invention from the content disclosed in this specification.

[0056] Terminology Definition

[0057] In this application, the term "emedastine" generally refers to a selective H1 receptor antagonist, including its free base form and its pharmaceutically acceptable salt form, unless the context otherwise requires. The compound may also be called emedastine or emedastine. The chemical name of emedastine may be: 1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazaheptane-1-yl)benzimidazole, and the molecular formula may be C1. 17 H 26 N4O. The CAS number for Imesitine can be 87233-61-2. Imesitine can have the following structure: .

[0058] In this application, the term "pharmaceutically acceptable salt" generally refers to a salt form that, when combined with the active pharmaceutical ingredient, is widely accepted in the pharmaceutical industry and neither impairs efficacy nor causes adverse reactions in the body. This term includes, but is not limited to, acid addition salts and base addition salts, provided they meet pharmaceutical, safety, and toxicological requirements and are suitable for pharmaceutical use. Pharmaceutically acceptable salts of emesine are typically its acid addition salts, including but not limited to: fumarate, citrate, tartrate, oxalate, and hydrochloride.

[0059] In this application, the term "emedastine fumarate" generally refers to a salt formed by emedastine and fumaric acid, such as emedastine difumarate. Emedastine fumarate can exist in different crystal forms or hydrated states. Unless otherwise stated, emedastine fumarate as described in this application generally refers to a compound formed by two molecules of fumaric acid and emedastine, i.e., emedastine difumarate. The chemical name of emedastine difumarate is 1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazaheptane-1-yl)benzimidazole difumarate. The molecular formula of emedastine difumarate can be C1. 25 H 34 The CAS number for N4O9, emesitin difumarate, can be 87233-62-3.

[0060] In this application, the term "pH adjuster" generally refers to a class of components used to adjust the pH value of a formulation to bring it within a pharmaceutically acceptable range. pH adjusters applicable to this application may include acidic components, basic components, or buffer systems. Suitable pH adjusters include, but are not limited to, citric acid, hydrochloric acid, acetic acid, sodium hydroxide, potassium hydroxide, sodium citrate / citric acid systems, and phosphate buffer systems.

[0061] In this application, the term "metal ion complexing agent" generally refers to a pharmaceutically acceptable excipient capable of forming stable complexes with metal ions (such as Ca²⁺, Mg²⁺, Fe³⁺, etc.). Its function typically includes inhibiting formulation instability caused by metal ions (such as oxidative degradation, flocculation, discoloration, etc.) or enhancing the stability and bioavailability of the active ingredient. Metal ion complexing agents applicable to this application include, but are not limited to: edetic acid (i.e., ethylenediaminetetraacetic acid, EDTA), its sodium salts (such as EDTA-2Na or EDTA-4Na), citric acid, tartaric acid, phytic acid, and their salts.

[0062] In this application, the term "osmolarity modifier" generally refers to a pharmaceutically acceptable excipient that can be used to adjust the osmotic pressure of a formulation to improve its compatibility with physiological conditions. The osmolarity modifier may be used alone or in combination with other excipients to give the composition an osmotic pressure close to that of the nasal cavity or other administration sites, thereby reducing irritation, enhancing comfort, and promoting drug absorption. Osmolarity modifiers suitable for use in this application include, but are not limited to, sodium chloride, propylene glycol, glycerol, glucose, or combinations thereof.

[0063] In this application, the term "thickener" generally refers to a pharmaceutically acceptable excipient used to increase the viscosity of a nasal formulation system to improve its physical stability, prolong the retention time of the drug on the nasal mucosa, or enhance the user experience. Thickeners suitable for use in this application include, but are not limited to, one or more of the following: sugars such as sucrose; natural or semi-synthetic polysaccharides such as pectin, sodium carboxymethyl cellulose (CMC-Na), and hydroxypropyl methylcellulose (HPMC); co-treated cellulose materials such as microcrystalline cellulose-sodium carboxymethyl cellulose co-treated products; and synthetic polymers such as povidone. The thickeners may be used alone or in combination.

[0064] In this application, the term "humectant" generally refers to a pharmaceutically acceptable excipient that can retain or increase moisture in a formulation, reduce dryness or irritation of the nasal mucosa, thereby improving user comfort and drug delivery. The humectant can function by adjusting the osmotic pressure and water activity of the formulation, or by prolonging drug retention time by forming a protective hydration layer on the nasal mucosa. Humectants suitable for nasal formulations include, but are not limited to: polyols (such as glycerin, sorbitol, propylene glycol), sugar alcohols (such as mannitol, xylitol, erythritol), and sugars (such as sucrose, lactose), etc.

[0065] It should be noted that some of the excipients described in this application may have multiple pharmaceutical uses. For example, glucose can be used as an osmotic pressure regulator, as well as a thickener or humectant. Unless otherwise specified, the use of a particular class of excipients in this application does not exclude the possibility that they may also have other functions in the formulation.

[0066] In this application, the term "absorption enhancer" generally refers to an additive that can increase the rate and / or extent of absorption of an active ingredient (such as emesine or a pharmaceutically acceptable salt thereof) through the nasal mucosa. Absorption enhancers can act through a variety of mechanisms, including but not limited to: altering mucosal permeability, promoting drug retention on the mucosal surface, inhibiting drug degradation, or stimulating the expansion of intercellular spaces. Absorption enhancers applicable to this application may include, but are not limited to, one or more of the following categories: fatty acids and their salts (e.g., sodium caprylate, sodium decanoate); bile salts (e.g., sodium taurine deoxycholate); phospholipids (e.g., lecithin, distearate phosphatidylcholine, etc.); polyethylene glycol and its derivatives (e.g., PEG-400, PEG-40 hydrogenated castor oil, etc.); alkyl glycoside surfactants (e.g., lauryl glucoside, decyl glucoside, dodecyl maltodextrin); cyclodextrin and its derivatives (e.g., β-cyclodextrin, hydroxypropyl-β-cyclodextrin, methyl-β-cyclodextrin); and other pharmaceutically acceptable absorption enhancers that have been reported in the literature or pharmacopoeia to enhance nasal absorption. The above absorption enhancers may be used alone or in combination.

[0067] In this application, the term "sterile" generally refers to the absence of detectable viable microorganisms during the preparation, filling, packaging, and storage of a formulation and its container system under routine microbiological testing conditions (such as culture medium inoculation method, membrane filtration method, etc.). The term "sterile" can be obtained through aseptic manufacturing processes (such as aseptic preparation and filling in a clean environment) or through terminal sterilization methods (such as filtration sterilization, heat sterilization, irradiation sterilization, etc.), and is not limited to any specific process route.

[0068] In this application, the term "microbial inhibitor" generally refers to a pharmaceutically acceptable excipient that can inhibit the growth of microorganisms in a formulation, thereby extending the shelf life of the formulation and ensuring its safety of use. The main function of a microbial inhibitor is to prevent the proliferation of microorganisms such as bacteria, fungi, or yeasts caused by exogenous contamination during the production, storage, or use of the formulation. Microbial inhibitors applicable to this application include, but are not limited to, quaternary ammonium salts (such as benzalkonium chloride), alcohols (such as benzyl alcohol, phenethyl alcohol), organic acids and their salts (such as benzoic acid, sodium benzoate, potassium sorbate), parabens (such as methylparaben, ethylparaben, propylparaben), or combinations thereof.

[0069] In this application, the term "nasal preparation" generally refers to a pharmaceutical preparation administered via the nasal route, which may be in liquid, semi-solid, or powder form, with water or a pharmaceutically acceptable solvent as the carrier, and may contain appropriate excipients (such as pH adjusters, osmotic pressure adjusters, thickeners, absorption enhancers, antibacterial agents, etc.). The purpose of nasal preparations is to deliver the active ingredient through the nasal mucosa to exert local or systemic pharmacological effects.

[0070] In this application, the term "spray" generally refers to a nasal liquid formulation that is atomized into fine droplets by a mechanical pump, manual capping, or other atomizing device. Sprays are propellant-free, and their droplet size distribution is typically in the range of tens of micrometers, making them suitable for local deposition in the nasal cavity.

[0071] In this application, the term "aerosol" generally refers to a nasal preparation that utilizes a propellant (such as a Freon substitute, compressed gas, etc.) to atomize into an aerosol. When used, an aerosol relies on internal pressure to release droplets, and the droplet size can be adjusted according to the formulation and device.

[0072] In this application, the term "nasal drops" generally refers to a liquid nasal preparation that is administered directly into the nasal cavity in solution form, usually without the aid of a nebulizer, and the method of administration is dripping.

[0073] In this application, the term "aqueous composition" generally refers to a pharmaceutical composition in which water is the primary solvent or dispersion medium, wherein the water may be purified water, water for injection, or other water that meets pharmaceutical standards. The aqueous composition may also contain appropriate amounts of pharmaceutically acceptable excipients such as co-solvents, surfactants, buffers, osmotic pressure regulators, thickeners, absorption enhancers, and antibacterial agents. Unless otherwise stated, the term "aqueous composition" in this application primarily refers to liquid formulations, preferably solutions or colloidal dispersions suitable for local nasal administration.

[0074] In this application, the term "allergic rhinitis" generally refers to a chronic or recurrent disease characterized by inflammation of the nasal mucosa, induced by inhaled allergens, typically an IgE-mediated type I hypersensitivity reaction. Typical clinical manifestations include, but are not limited to, recurrent sneezing, runny nose, nasal congestion, and nasal itching. Allergic rhinitis can be classified according to the nature of the allergen or its pathogenesis into seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR). Seasonal allergic rhinitis is characterized by sneezing, runny nose, nasal congestion, and nasal itching that occur during a specific season, often caused by seasonal allergens such as pollen, and is clinically often referred to as hay fever or pollinosis. Perennial allergic rhinitis typically refers to an inflammatory disease of the nasal cavity caused by common perennial allergens such as dust mites, mold, and animal dander. Its typical manifestations include long-term or year-round nasal congestion, intermittent or persistent runny nose, sneezing, and nasal itching, with some patients experiencing worsening symptoms at night or in the early morning. Unless otherwise specified, the term "allergic rhinitis" as used in this application broadly encompasses the two types of diseases and their clinical symptoms.

[0075] In this application, the term "conjunctivitis" generally refers to an inflammatory disease occurring on the conjunctiva of the eyeball or palpebral conjunctiva, with typical clinical manifestations including, but not limited to, redness, tearing, foreign body sensation, itching, and increased discharge. The causes of conjunctivitis can be infectious (e.g., caused by bacteria, viruses, fungi, or chlamydia) and non-infectious (e.g., caused by allergies, irritants (such as chemicals, ultraviolet radiation), dry eye, etc.). Allergic conjunctivitis is a common type, often triggered by inhaled allergens such as pollen, dust mites, and animal dander, and is often accompanied or occurs simultaneously with allergic rhinitis. Unless otherwise specified, the term "conjunctivitis" as used in this application broadly encompasses conjunctivitis of the aforementioned different causes, and preferably refers to allergic conjunctivitis.

[0076] In this application, the term "treatment" generally refers to the management of a subject's symptoms or disease through administration of medication or other interventions, including but not limited to: prevention (preventing the occurrence of disease or reducing the risk of disease occurrence), relief (reducing the severity of symptoms), improvement (shortening the course of the disease or alleviating symptoms), stabilization (delaying disease progression or preventing the condition from worsening), and cure.

[0077] In this application, the term "effective amount" refers to a drug dose sufficient to produce a desired therapeutic effect in a subject, which may include, but is not limited to, relief, improvement, control, or prevention of symptoms. The effective amount may vary due to individual patient differences, dosing regimen, and symptom severity.

[0078] As used in the specification and claims, the singular forms “a,” “an,” and “the (described)” include the plural forms unless the context clearly indicates otherwise.

[0079] All numerical values ​​or expressions relating to component quantities, etc., used in this application should be understood to be modified by the word "about" in all cases. The term "about," when referring to a quantity or range of values, means that the quantity or range is an approximation within experimental variability (or within statistical experimental error), and therefore the quantity or range of values ​​may vary, for example, between ±5. All ranges relating to the same component or property include endpoints that can be independently combined. Because these ranges are continuous, they include every value between a minimum and a maximum value. It should also be understood that any numerical range referenced in this application is intended to include all subranges within that range.

[0080] When this application defines a range in relation to physical properties such as molecular weight or chemical properties, it should include all combinations and sub-combinations of the range and specific embodiments within it. The term "comprising" (and related terms such as "containing," "including," "having," or "comprise") includes embodiments that are, for example, any combination of substances, compositions, methods, or processes, which "consist of the described features" or "consist substantially of the described features."

[0081] The term "and / or" as used in this application should be understood as "either one or both" of the associated components, meaning that the components exist jointly in some cases and separately in others. Multiple components listed using "and / or" should be understood in the same way as "one or more" associated components. Other components may optionally exist, whether related to or unrelated to those specifically identified components, except for the components specifically identified in the "and / or" clause. Therefore, as a non-limiting example, the reference to "A and / or B" when used to connect an open-ended phrase such as "including" may, in one embodiment, refer only to A (optionally including components other than B); in another embodiment, refer only to B (optionally including components other than A); in yet another embodiment, refer to A and B (optionally including other components), and so on. Invention Details

[0083] On one hand, this application provides a nasal preparation, particularly an aqueous nasal composition containing emesine or a pharmaceutically acceptable saline thereof. The preparation of the present invention exhibits good stability, absorbability, and patient compliance in the treatment of allergic rhinitis and / or conjunctivitis.

[0084] Active ingredients

[0085] In some embodiments, the active ingredient of the nasal formulation described in this application is only emesostine or a pharmaceutically acceptable salt thereof. Preferably, the pharmaceutically acceptable salt is emesostine fumarate, such as emesostine difumarate. In the nasal formulation described in this application, the content of the active ingredient can be selected in the range of 0.01% to 5% (w / v%), preferably 0.05% to 2.5% (w / v%), and more preferably 0.1% to 1% (w / v%). In some embodiments, the nasal formulation described in this application contains 0.01% to 5% (w / v%) of emesostine fumarate.

[0086] Physicochemical properties

[0087] In some embodiments, the nasal preparations described in this application may have at least one of the following physicochemical properties: a pH value of 3.0 to 8.0; a viscosity of 0.5 to 5.0 mPa·s (which can be measured, for example, at 20°C); and an osmolar concentration of 260 to 350 mOsmol / kg.

[0088] In some embodiments, the pH value of the nasal preparation described in this application can be 3.0 to 8.0. In some embodiments, the pH value of the nasal preparation described in this application can be 5.0 to 6.0. In some embodiments, the pH value of the nasal preparation described in this application can be about 5.5. The pH value described in this application can be measured using a conventional pH meter, for example, at 20°C or 25°C.

[0089] In some embodiments, the viscosity of the nasal preparation described in this application at 20°C can be 0.5~5.0 mPa·s. In some embodiments, the viscosity of the nasal preparation described in this application at 20°C can be 1.0~3.0 mPa·s. In some embodiments, the viscosity of the nasal preparation described in this application at 20°C can be about 2.0 mPa·s. The viscosity described in this application can be measured using a rotational viscometer (such as a Brookfield viscometer), for example, at 20°C ± 2°C.

[0090] In some embodiments, the osmolality of the nasal preparation described in this application can be 260~350 mOsmol / kg. In some embodiments, the osmolality of the nasal preparation described in this application can be 285~310 mOsmol / kg. In some embodiments, the osmolality of the nasal preparation described in this application can be about 290 mOsmol / kg. The osmolality described in this application can be detected using an osmometer with the freezing point depression method, for example, at 20℃±2℃. Other equivalent methods known to those skilled in the art (e.g., vapor pressure osmolarity method) can also be used to detect the osmolality.

[0091] In some embodiments, the nasal preparation described in this application has a pH of about 5.5, a viscosity of about 2.0 mPa·s at 20°C, and an osmolar concentration of about 290 mOsmol / kg.

[0092] pH adjuster

[0093] Formulation stability is related to pH value. To ensure that the formulation has appropriate stability and that the pH value of the formulation is within the range that the nasal mucosa can tolerate, this application uses a pH adjuster to adjust the pH value of the nasal formulation.

[0094] In some embodiments, the nasal preparations described in this application contain a pH adjuster, which may be selected from citric acid, sodium citrate, sodium hydroxide, and / or hydrochloric acid.

[0095] In some embodiments, the citric acid content may be 0.001% to 2% (w / v%). In some embodiments, the citric acid content may be 0.01% to 0.2% (w / v%). In some embodiments, the citric acid content may be 0.0048% to 0.12% (w / v%). In some embodiments, the citric acid content may be 0.03% to 0.08% (w / v%), for example, about 0.048% (w / v%).

[0096] In some embodiments, the sodium citrate content may be 0.001% to 1% (w / v%). In some embodiments, the sodium citrate content may be 0.005% to 0.05% (w / v%). In some embodiments, the sodium citrate content may be 0.008% to 0.02% (w / v%). In some embodiments, the sodium citrate content may be 0.007% to 0.02% (w / v%), for example, about 0.008% (w / v%).

[0097] In some embodiments, the pH of the nasal preparation is adjusted to 3.0-8.0 using sodium hydroxide or hydrochloric acid. In some embodiments, the pH is 5.0-6.0. In some embodiments, the pH is approximately 5.5.

[0098] Metal ion complexing agents

[0099] To prevent the active ingredients from being catalytically degraded by metal ions, an appropriate amount of metal ion chelating agent may be added to the nasal formulation of this application.

[0100] In some embodiments, the nasal formulation of this application contains a metal ion complexing agent, the content of which may be 0.001% to 0.1% (w / v%). In some embodiments, the content of the metal ion complexing agent may be 0.005% to 0.05% (w / v%), for example, about 0.01% (w / v%).

[0101] In some embodiments, the metal ion complexing agent may include disodium edetate (EDTA-2Na). In some embodiments, the content of disodium edetate may be 0.001% to 0.1% (w / v%). In some embodiments, the content of disodium edetate may be 0.005% to 0.05% (w / v%), for example, about 0.01% (w / v%).

[0102] Osmotic pressure regulator

[0103] To reduce the irritation of the nasal mucosa caused by hypotonicity or hypertonicity, the nasal formulations of this application may use an osmotic pressure regulator to adjust the osmotic pressure of the formulation to isotonicity.

[0104] In some embodiments, the nasal formulation of this application contains an osmotic pressure regulator, which may be selected from sodium chloride, propylene glycol, glycerin, glucose, mannitol, sorbitol, or combinations thereof.

[0105] In some embodiments, the osmotic pressure regulator may include sodium chloride, with a content of 0.05% to 2% (w / v%). In some embodiments, the nasal preparation of this application includes sodium chloride, with a content of 0.2% to 1.0% (w / v%). In some embodiments, the content of sodium chloride may be 0.7% to 1% (w / v%). In some embodiments, the content of sodium chloride may be 0.7% to 0.8% (w / v%), for example, about 0.75% (w / v%).

[0106] In some embodiments, the osmotic pressure regulator may include propylene glycol, with a content of 0.5% to 5% (w / v%). In some embodiments, the nasal formulation of this application includes propylene glycol, with a content of 1% to 3% (w / v%), for example, about 2.6% (w / v%).

[0107] In some embodiments, the osmotic pressure regulator may include glycerol at a content of 0.5% to 10% (w / v%). In some embodiments, the nasal formulation of this application includes glycerol at a content of 1% to 5% (w / v%), for example, about 2.6% (w / v%).

[0108] In some embodiments, the osmotic pressure regulator may include glucose at a content of 0.5% to 10% (w / v%). In some embodiments, the nasal formulation of this application comprises glucose at a content of 3% to 7% (w / v%), for example, about 5% (w / v%).

[0109] In some embodiments, the osmotic pressure regulator may include mannitol, with a content of 0.5% to 10% (w / v%). In some embodiments, the nasal formulation of this application includes mannitol, with a content of 3% to 7% (w / v%), for example, about 5.48% (w / v%).

[0110] In some embodiments, the osmotic pressure regulator may include sorbitol, which may be present in a concentration of 0.5% to 10% (w / v%). In some embodiments, the nasal formulation of this application contains sorbitol, which may be present in a concentration of 3% to 7% (w / v%), for example, about 5% (w / v%).

[0111] In some embodiments, the nasal preparations described in this application may contain one, two, or more osmoregulators. In some embodiments, the nasal preparations described in this application may contain sodium chloride and propylene glycol, sodium chloride and glycerin, sodium chloride and sorbitol, sodium chloride and mannitol, or any combination of two or more other osmoregulators.

[0112] In some embodiments, some of the osmotic pressure regulators described in this application may also have other functions. For example, glycerol, propylene glycol, sorbitol, and mannitol can not only regulate osmotic pressure but also act as humectants, improving the local moisture content of the nasal cavity and the stability of the medication solution. In addition to regulating osmotic pressure, glucose can also increase the viscosity of the medication solution to a certain extent, thereby playing a thickening role.

[0113] Thickener

[0114] To improve the viscosity of the formulation and enable it to have suitable droplet distribution characteristics during spraying, the nasal formulation of this application may further contain a thickener, thereby achieving better delivery efficiency and targeting. Simultaneously, the thickener can prolong the residence time of the drug on the nasal mucosa, reducing the rapid clearance or swallowing of the drug solution, thus enhancing the local efficacy of the drug.

[0115] In some embodiments, the nasal formulation of this application contains a thickener, which may be selected from sucrose, pectin, microcrystalline cellulose-sodium carboxymethyl cellulose co-processed material, sodium carboxymethyl cellulose, hydroxypropyl methylcellulose (HPMC), povidone (PVP), or a combination thereof.

[0116] In some embodiments, the thickener includes hydroxypropyl methylcellulose. The hydroxypropyl methylcellulose contained in the nasal formulation of this application can be hydroxypropyl methylcellulose with a viscosity of about 1000-10000 mPa·s when its 2% aqueous solution is measured at 20°C, for example, it can be hydroxypropyl methylcellulose with a viscosity of about 4000 mPa·s when its 2% aqueous solution is measured at 20°C. For example, the hydroxypropyl methylcellulose can be pharmaceutical grade hydroxypropyl methylcellulose with a methoxy group content of about 28-30%, a hydroxypropoxy group content of about 7-12%, and a viscosity of about 4000 mPa·s when its 2% aqueous solution is measured at 20°C. In the nasal formulation of this application, the content of hydroxypropyl methylcellulose can be 0.005%-5% (w / v%). In some embodiments, the content of hydroxypropyl methylcellulose can be 0.1% (w / v%)-0.2% (w / v%). In some embodiments, the content of hydroxypropyl methylcellulose can be 0.05%-2.0% (w / v%). In some embodiments, the content of hydroxypropyl methylcellulose may be 0.05% to 1.5% (w / v%), for example, about 0.1% (w / v%).

[0117] In some embodiments, the thickener comprises povidone. In the nasal formulation of this application, the content of povidone can be 0.01% to 2% (w / v%). In some embodiments, the content of povidone can be 0.05% to 1.0% (w / v%).

[0118] In some embodiments, the thickener includes pectin. In the nasal formulations of this application, the pectin content can be 0.001% to 1% (w / v%). In some embodiments, the pectin content can be 0.005% to 0.1% (w / v%).

[0119] In some embodiments, the thickener comprises sodium carboxymethyl cellulose. In the nasal formulation of this application, the content of sodium carboxymethyl cellulose can be 0.01% to 2% (w / v%). In some embodiments, the content of sodium carboxymethyl cellulose can be 0.05% to 1.0% (w / v%).

[0120] In some embodiments, the thickener comprises a microcrystalline cellulose-sodium carboxymethyl cellulose co-processed compound. In the nasal formulations of this application, the content of the microcrystalline cellulose-sodium carboxymethyl cellulose co-processed compound can be 0.05% to 4.0% (w / v%); in some embodiments, the content of the microcrystalline cellulose-sodium carboxymethyl cellulose co-processed compound can be 0.5% to 2.2% (w / v%).

[0121] In some embodiments, the thickener comprises sucrose. In the nasal formulation of this application, the sucrose content may be 0.1% to 5% (w / v%). In some embodiments, the sucrose content may be 0.5% to 2% (w / v%).

[0122] In some embodiments, the nasal preparations described in this application may contain one, two, or more thickeners. In some embodiments, some of the thickeners described in this application may also have other functions. For example, sucrose at a certain concentration can not only increase the viscosity of the preparation but also regulate the osmotic pressure to a certain extent; hydroxypropyl methylcellulose, in addition to improving the droplet size distribution, can also improve the physical stability of the preparation during storage; povidone, in addition to improving viscosity, can also act as a co-solvent to promote the solubility and stability of some components in the preparation.

[0123] Moisturizer

[0124] In some embodiments, the nasal preparations described in this application may not contain a moisturizer. Even without a moisturizer, the nasal preparations can still maintain good stability and efficacy.

[0125] In some embodiments, the nasal preparations described in this application include a humectant to improve the local wettability of the nasal solution and reduce mucosal dryness. In some embodiments, the humectant content may be 0.5% to 10% (w / v%). In some embodiments, the humectant content may be 1% to 5% (w / v%).

[0126] In some embodiments, the moisturizer may include sorbitol and / or mannitol. In some embodiments, the nasal formulation of this application comprises sorbitol at a content of 0.5% to 10% (w / v%). In some embodiments, the sorbitol content may be 1% to 5% (w / v%), for example, about 4.7% (w / v%). In some embodiments, the nasal formulation of this application comprises mannitol at a content of 0.5% to 10% (w / v%). In some embodiments, the mannitol content may be 1% to 5% (w / v%), for example, about 4.2% (w / v%).

[0127] In some embodiments, the moisturizer described in this application may also be one of the aforementioned osmotic pressure regulators. For example, propylene glycol and glycerin, when used as osmotic pressure regulators, can also exert a moisturizing effect, thereby improving the local environment of the nasal cavity without introducing additional excipients.

[0128] Absorption enhancer

[0129] In some embodiments, the nasal formulations described in this application may not contain an absorption enhancer. Even without an absorption enhancer, the nasal formulations can still achieve effective nasal delivery of emesine or its salts and good efficacy.

[0130] In some embodiments, the nasal formulations described in this application include an absorption enhancer to further improve the penetration and absorption of the active ingredient through the nasal epithelium.

[0131] In some embodiments, the absorption enhancer may be selected from fatty acids, bile salts, phospholipids, polyethylene glycol and its derivatives, alkyl glycosides, cyclodextrin and its derivatives, or combinations thereof. In some embodiments, the absorption enhancer may include: sodium caprylate, sodium decanoate, sodium taurine deoxycholate, lecithin, distearate phosphatidylcholine, PEG-400, PEG-40 hydrogenated castor oil, lauryl glucoside, decyl glucoside, dodecyl maltodextrin, β-cyclodextrin, hydroxypropyl-β-cyclodextrin, methyl-β-cyclodextrin, or combinations thereof.

[0132] In some embodiments, the absorption enhancer comprises dodecyl maltodextrin. In some embodiments, the nasal formulation of this application comprises dodecyl maltodextrin in a content of 0.001% to 0.5% (w / v%). In some embodiments, the content of dodecyl maltodextrin may be 0.005% to 0.05% (w / v%), for example, about 0.01% (w / v%).

[0133] antibacterial agent

[0134] In some embodiments, the nasal preparations described in this application are non-sterile preparations and require the addition of antibacterial agents.

[0135] In some embodiments, the antibacterial agent is selected from quaternary ammonium salts, alcohols, organic acids and their salts, parabens, or combinations thereof. In some embodiments, the antibacterial agent may include: benzalkonium chloride, benzyl alcohol, phenethyl alcohol, potassium sorbate, sodium benzoate, or combinations thereof.

[0136] In some embodiments, the antibacterial agent includes benzalkonium chloride. In some embodiments, the nasal preparation of this application contains benzalkonium chloride at a content of 0.001% to 0.5% (w / v%). In some embodiments, the content of benzalkonium chloride may be 0.005% to 0.05% (w / v%), for example, about 0.015% (w / v%).

[0137] In some embodiments, the nasal preparations described in this application are sterile preparations, requiring no additional antibacterial agents. The sterile preparations described in this application can be achieved in various ways, such as: being prepared using conventional sterilization processes (e.g., high-temperature, high-pressure steam sterilization, filtration sterilization, irradiation sterilization, etc.); and / or being prepared and filled under sterile conditions, or using packaging devices with bacterial barrier functions, thereby maintaining the sterility of the preparation during storage and use without the need for additional antibacterial agents.

[0138] Nasal preparations

[0139] In some embodiments, the nasal preparation described in this application comprises the following ingredients: emesartan fumarate, in a content of 0.01% to 5% (w / v%); citric acid, in a content of 0.001% to 2% (w / v%); sodium citrate, in a content of 0.001% to 1% (w / v%); disodium edetate, in a content of 0.001% to 0.1% (w / v%); sodium chloride, in a content of 0.05% to 2% (w / v%); hydroxypropyl methylcellulose, in a content of 0.005% to 5% (w / v%); and the pH is adjusted to 3.0 to 8.0 by sodium hydroxide. In some embodiments, the aforementioned nasal preparation further comprises benzalkonium chloride, in a content of 0.001% to 0.5% (w / v%).

[0140] In some embodiments, the nasal formulation of this application comprises the following components: 0.4% (w / v%) emestin fumarate, 0.048% (w / v%) citric acid, 0.008% (w / v%) sodium citrate, 0.01% (w / v%) disodium edetate, 0.75% (w / v%) sodium chloride, and 0.1% (w / v%) hydroxypropyl methylcellulose, with the pH adjusted to 5.5 by sodium hydroxide. In some embodiments, the aforementioned nasal formulation further comprises benzalkonium chloride at a content of 0.015% (w / v%).

[0141] In some embodiments, the nasal formulation described in this application, in addition to containing emestin fumarate, citric acid, sodium citrate, disodium edetate, sodium chloride, hydroxypropyl methylcellulose, and optionally benzalkonium chloride, may also contain one or two of the following components: povidone, propylene glycol, glycerin, glucose, mannitol, sorbitol, and dodecyl maltodextrin.

[0142] The nasal preparations described in this application can be sprays, aerosols, and nasal drops. In some embodiments, the nasal preparation described in this application is a spray, and when measured at a spray distance of 3 cm or 6 cm, its droplet size distribution has the following characteristics: D50 particle size is 30~150 μm, the proportion of droplets with a particle size less than 10 μm is less than 5%, and the droplet size distribution span is less than 3.0. In some embodiments, the spray droplet size distribution of the spray, when measured at a spray distance of 3 cm or 6 cm, has the following characteristics: D50 particle size is 45~60 μm, the proportion of droplets with a particle size less than 10 μm is less than 2%, and the droplet size distribution span is less than 2.0.

[0143] The nasal formulations described in this application can be aqueous compositions, wherein the components are dissolved or dispersed in water to ensure good nasal tolerability and formulation stability. In some embodiments, the solvent for the nasal formulations described in this application is water, such as purified water, water for injection, or sterilized water. In some embodiments, the aqueous composition may also contain a small amount of pharmaceutically acceptable co-solvents or excipients to improve the solubility and compatibility stability of the active ingredient or excipients.

[0144] Pharmaceutical uses and treatments

[0145] On the other hand, this application also provides the use of the nasal preparation described herein in the preparation of a medicament for the treatment of allergic rhinitis and / or conjunctivitis.

[0146] On the other hand, this application also provides a method for treating allergic rhinitis and / or conjunctivitis, comprising administering an effective amount of the nasal preparation described in this application to a subject in need.

[0147] On the other hand, this application also provides the use of the nasal preparation described in this application in the treatment of allergic rhinitis and / or conjunctivitis.

[0148] In some embodiments, the allergic rhinitis includes seasonal allergic rhinitis and perennial allergic rhinitis.

[0149] In some embodiments, the conjunctivitis includes allergic conjunctivitis, including cases that occur alone or concurrently with allergic rhinitis.

[0150] The treatment of allergic rhinitis and / or conjunctivitis described in this application may include, but is not limited to: symptom relief (e.g., reducing or eliminating nasal symptoms such as itchy nose, sneezing, runny nose, and nasal congestion, as well as conjunctivitis-related symptoms such as itchy eyes, tearing, and red eyes), symptom improvement (e.g., reducing the frequency or duration of symptoms and improving the patient's quality of life), disease control and stabilization (e.g., reducing the frequency and intensity of acute attacks and delaying or preventing the condition from worsening through long-term or regular use); and preventive effects (e.g., reducing the likelihood of symptom occurrence and reducing adverse reactions caused by allergen exposure).

[0151] In some embodiments, the nasal preparations described herein are administered topically through the nasal cavity, for example, via a spray, aerosol, or nasal drops. In some embodiments, the administration frequency may be once daily to several times daily.

[0152] In some embodiments, the "subject" referred to in this application may be an individual requiring treatment for allergic rhinitis and / or conjunctivitis. The subject may be a human patient, including adults and children. In some embodiments, the subject is an individual suffering from seasonal allergic rhinitis, perennial allergic rhinitis, allergic conjunctivitis, or comorbidities thereof. In some embodiments, the subject may also be an individual requiring prevention of allergic reactions or reduction of the risk of symptom occurrence.

[0153] Preparation method

[0154] On the other hand, this application provides a method for preparing the nasal formulation, which includes dissolving emestin or a pharmaceutically acceptable salt thereof, and other components of the nasal formulation (e.g., excipients required for the formulation) in water capable of achieving a desired concentration range in the resulting solution.

[0155] In some embodiments, the preparation method described in this application may include one or more of the following steps:

[0156] a) Dissolution: Dissolve the active ingredient (such as emestin fumarate) and soluble excipients (such as citric acid, sodium citrate, sodium chloride, etc.) in purified water;

[0157] b) Dispersion: Disperse or dissolve poorly soluble or thickening excipients (such as hydroxypropyl methylcellulose, povidone, etc.) in water. If necessary, they can be pre-dissolved or pre-hydrated under stirring conditions.

[0158] c) Mixing: Mix the above solution / dispersion and stir to make it homogeneous;

[0159] d) pH adjustment: Adjust the pH to 3.0–8.0 using a pharmaceutically acceptable acid or base (such as sodium hydroxide);

[0160] e) To replenish the solvent: Add purified water to the target volume and stir well; and

[0161] f) Filtration: If necessary, sterilization filtration can be performed through a filter membrane (such as a 0.22 μm filter membrane).

[0162] In some embodiments, the formulation may be further sterilized (e.g., moist heat sterilization, irradiation sterilization) or aseptically filled into nasal spray bottles, nasal drop bottles or aerosol devices.

[0163] In some embodiments, the preparation method may include filling the prepared drug solution into a packaging device with bacterial barrier function to ensure that sterility is maintained without the addition of antibacterial agents.

[0164] In some embodiments, the preparation order of the formulation described in this application may differ. For example, emesine or its salt may be dissolved first, followed by the addition of other excipients; alternatively, a buffer solution (such as citrate / sodium citrate buffer) may be prepared first, followed by the addition of the active ingredient and other excipients in sequence.

[0165] Packaging equipment

[0166] In some embodiments, the nasal preparations described in this application can be packaged into a suitable nasal delivery device for convenient clinical use.

[0167] On the other hand, this application also provides a packaging device containing the nasal preparation described in this application. In some embodiments, the packaging device is a nasal spray bottle equipped with a nozzle and a pump device for controlling the dosage, which ensures a stable dosage and uniform droplet distribution for each application. In some embodiments, the packaging device has a bacterial barrier function, for example, by introducing a bacterial barrier membrane, a one-way valve, or other pharmaceutically acceptable filter element into the pump head or valve section, thereby effectively preventing microbial contamination introduced by air recirculation during repeated use, even when the preparation is non-sterile and does not contain bacteriostatic agents.

[0168] In some embodiments, the packaging device may be a multi-dose container suitable for repeated press-to-use. In some embodiments, the packaging device may be a single-dose container for single-use administration. In some embodiments, the bottle material of the packaging device may be selected from pharmaceutically acceptable plastics or glass, such as polyethylene (PE), polypropylene (PP), polyethylene terephthalate (PET), borosilicate glass, etc.

[0169] In some embodiments, the packaging device may further include a protective cap to prevent the nozzle from becoming contaminated during transport and storage. In some embodiments, the packaging device may be an opaque or light-proof bottle to reduce the impact of light on the stability of the formulation.

[0170] This application provides the following implementation methods:

[0171] 1. A nasal preparation comprising only emeslin or a pharmaceutically acceptable salt thereof as its active ingredient.

[0172] 2. In the nasal preparation according to Embodiment 1, the pharmaceutically acceptable salt of emestin includes emestin fumarate.

[0173] 3. The nasal preparation according to any one of embodiments 1-2, wherein the content of the active ingredient is 0.01% to 5% (w / v%).

[0174] 4. The nasal preparation according to any one of embodiments 1-3, having at least one of the following physicochemical properties:

[0175] a) pH value is 3.0~8.0;

[0176] b) Viscosity is 0.5~5.0 mPa·s;

[0177] c) The osmolar concentration is 260~350 mOsmol / kg.

[0178] 5. The nasal preparation according to any one of embodiments 1-4, wherein the nasal preparation comprises a pH adjuster, a metal ion complexing agent, an osmotic pressure regulator, and a thickener.

[0179] 6. The nasal preparation according to embodiment 5, wherein the pH adjuster is selected from citric acid, sodium citrate, sodium hydroxide and / or hydrochloric acid.

[0180] 7. In the nasal preparation according to Embodiment 6, the content of citric acid is 0.001% to 2% (w / v%), and the content of sodium citrate is 0.001% to 1% (w / v%).

[0181] 8. The nasal preparation according to embodiment 5, wherein the metal ion chelating agent is disodium edetate.

[0182] 9. In the nasal preparation according to Embodiment 8, the content of disodium edetate is 0.001% to 0.1% (w / v%).

[0183] 10. The nasal preparation according to any one of embodiments 5-9, wherein the osmotic pressure regulator is selected from sodium chloride, propylene glycol, glycerol, glucose, or combinations thereof.

[0184] 11. In the nasal preparation according to Embodiment 10, the sodium chloride content is 0.05% to 2% (w / v%).

[0185] 12. The nasal preparation according to any one of embodiments 10-11, wherein the content of propylene glycol, glycerol or glucose is 0.5% to 10% (w / v%).

[0186] 13. The nasal formulation according to any one of embodiments 5-12, wherein the thickener is selected from sucrose, pectin, microcrystalline cellulose sodium carboxymethyl cellulose co-processed product, sodium carboxymethyl cellulose, hydroxypropyl methylcellulose, povidone, or combinations thereof.

[0187] 14. The nasal preparation according to embodiment 13, wherein the viscosity of the 2% aqueous solution of hydroxypropyl methylcellulose is about 1000 to 10000 mPa·s.

[0188] 15. The nasal formulation according to any one of embodiments 13-14, wherein the content of hydroxypropyl methylcellulose is 0.005% to 5% (w / v%).

[0189] 16. The nasal preparation according to embodiment 13, wherein the content of povidone is 0.01% to 2% (w / v%).

[0190] 17. The nasal preparation according to any one of embodiments 1-16 comprises the following components: emesartan fumarate, in a content of 0.01% to 5% (w / v%); citric acid, in a content of 0.001% to 2% (w / v%); sodium citrate, in a content of 0.001% to 1% (w / v%); disodium edetate, in a content of 0.001% to 0.1% (w / v%); sodium chloride, in a content of 0.05% to 2% (w / v%); hydroxypropyl methylcellulose, in a content of 0.005% to 5% (w / v%); and the pH is adjusted to 3.0 to 8.0 by sodium hydroxide.

[0191] 18. The nasal preparation according to any one of embodiments 1-17, comprising the following components: 0.4% (w / v%) emestin fumarate, 0.048% (w / v%) citric acid, 0.008% (w / v%) sodium citrate, 0.01% (w / v%) disodium edetate, 0.75% (w / v%) sodium chloride, 0.1% (w / v%) hydroxypropyl methylcellulose, and adjusted to pH 5.5 by sodium hydroxide.

[0192] 19. The nasal preparation according to any one of embodiments 1-18 further comprises a moisturizer.

[0193] 20. The nasal preparation according to embodiment 19, wherein the moisturizer is selected from sorbitol and / or mannitol.

[0194] 21. The nasal preparation according to embodiment 20, wherein the content of sorbitol or mannitol is 0.5% to 10% (w / v%).

[0195] 22. The nasal preparation according to any one of embodiments 1-21 further comprises an absorption enhancer.

[0196] 23. The nasal formulation according to embodiment 22, wherein the absorption enhancer is selected from fatty acids, bile salts, phospholipids, polyethylene glycol and its derivatives, alkyl glycosides, cyclodextrin and its derivatives, or combinations thereof.

[0197] 24. The nasal preparation according to embodiment 23, wherein the absorption enhancer is dodecyl maltodextrin, and the content of dodecyl maltodextrin is 0.01% (w / v%).

[0198] 25. The nasal preparation according to any one of embodiments 1-24, wherein the nasal preparation is a sterile preparation.

[0199] 26. The nasal preparation according to any one of embodiments 1-25 further comprises an antibacterial agent.

[0200] 27. The nasal preparation according to embodiment 26, wherein the antibacterial agent is selected from quaternary ammonium salts, alcohols, organic acids and their salts, parabens or combinations thereof.

[0201] 28. The nasal preparation according to embodiment 27, wherein the antibacterial agent is selected from benzalkonium chloride, benzyl alcohol, phenethyl alcohol, potassium sorbate, sodium benzoate, or a combination thereof.

[0202] 29. The nasal preparation according to any one of embodiments 26-28, wherein the antibacterial agent is benzalkonium chloride, and the content of benzalkonium chloride is 0.001% to 0.5% (w / v%).

[0203] 30. The nasal preparation according to any one of embodiments 1-29, wherein the dosage form is selected from one or more of the following: spray, aerosol and nasal drops.

[0204] 31. According to the nasal preparation of embodiment 30, the droplet size distribution of the spray has the following characteristics when measured at a spray distance of 3 cm or 6 cm: the D50 particle size is 30~150 μm, the proportion of droplets with a particle size less than 10 μm is less than 5%, and the droplet size distribution span is less than 3.0.

[0205] 32. The nasal preparation according to any one of embodiments 1-31 is an aqueous composition.

[0206] 33. A method for treating allergic rhinitis and / or conjunctivitis, comprising administering to a subject an effective amount of the nasal preparation described in any one of embodiments 1-32.

[0207] 34. Use of the nasal preparation of any one of embodiments 1-32 in the preparation of a medicament for treating allergic rhinitis and / or conjunctivitis.

[0208] 35. Use of the nasal preparation of any one of embodiments 1-32 in the treatment of allergic rhinitis and / or conjunctivitis.

[0209] 36. The method according to embodiment 33 or the use of any one of embodiments 34-35, wherein the allergic rhinitis includes seasonal allergic rhinitis and perennial allergic rhinitis.

[0210] 37. A method for preparing a nasal formulation according to any one of embodiments 1-32, comprising dissolving emesthetine or a pharmaceutically acceptable salt thereof, and the remaining components of the nasal formulation, in water capable of achieving a desired concentration range in the resulting solution.

[0211] 38. A packaging device comprising a nasal preparation according to any one of embodiments 1-32, comprising a nasal spray bottle provided with a nozzle and a pump device for controlling the dosage.

[0212] 39. The packaging device according to embodiment 38 has a bacterial barrier function.

[0213] The embodiments described below are not intended to be limited by any theory, but are merely for illustrating the nasal formulations and uses of this application, and are not intended to limit the scope of the invention.

[0214] Example

[0215] Example 1: Basic Formulation Design

[0216] Based on the physicochemical properties and dosage form characteristics of the active pharmaceutical ingredient, this application designed five formulations as shown in Table 1 and tested their stability.

[0217] Table 1: Formulation Composition and Dosage

[0218]

[0219] The above samples were stored at 50°C for 30 days. This application uses HPLC to analyze related substances in the samples.

[0220] 1. HPLC analysis conditions are shown in Table 2.

[0221] Table 2: Related materials conditions for HPLC analysis

[0222]

[0223] 2. Handling Method

[0224] Accurately measure an appropriate amount of the sample to be tested and quantitatively dilute it with a solvent (mobile phase A-mobile phase B-60:40) to prepare a solution containing approximately 1 mg per ml. Take appropriate amounts of the reference standard, impurity C reference standard, impurity D reference standard, impurity E reference standard, and impurity F reference standard, accurately weigh them, dissolve them in a solvent, and dilute them to prepare a solution containing approximately 1 mg of the active ingredient and 5 μg of each impurity per ml.

[0225] The test results are shown in Table 3.

[0226] Table 3: Formulation Stability

[0227]

[0228] Note: ND indicates not detected.

[0229] When the formulations were placed at 50℃ for 30 days, the properties of formulations 1, 2, and 5 did not show significant changes. Meanwhile, formulation 1 had the lowest level of related substances, showing better stability. Further optimization was carried out based on formulation 1.

[0230] Example 2: Study on the Dosage of Hydroxypropyl Methylcellulose

[0231] Based on Example 1, the dosage of hydroxypropyl methylcellulose was systematically investigated to evaluate the delivery characteristics and viscosity of the formulation. Samples were prepared with no hydroxypropyl methylcellulose, and with 0.5 mg / mL, 1 mg / mL, 1.5 mg / mL, and 2 mg / mL of hydroxypropyl methylcellulose, and the viscosity was measured. Simultaneously, the formulation was filled into a nasal spray device, and the droplet size and droplet distribution at 3 cm and 6 cm from the nozzle were directly measured using laser scattering. The results are shown in Table 4 below.

[0232] Table 4: Study on the Dosage of Hydroxypropyl Methylcellulose

[0233]

[0234] The viscosity of the solution increased with increasing hydroxypropyl methylcellulose dosage. Spray droplet size results showed that the droplet size at distances of 3 cm and 6 cm from the nozzle increased with increasing hydroxypropyl methylcellulose dosage.

[0235] Example 3 Study on the dosage of sodium chloride

[0236] Based on Example 1, the dosage of sodium chloride was investigated. The target osmolality of the formulation was 270–320 mOsmol / kg. The osmolality of the formulation was adjusted by controlling the dosage of sodium chloride to screen the appropriate range. The results are shown in Table 5 below.

[0237] Table 5: Study on Sodium Chloride Dosage

[0238]

[0239] The above results indicate that when the sodium chloride concentration in the formulation is 7 mg / ml to 8 mg / ml, the osmotic molar concentration of the drug solution is between 270 and 320 mOsmol / kg, and the preferred amount of sodium chloride in the formulation is 7.5 mg / ml.

[0240] Example 4: pH range study

[0241] Based on Example 1, the pH value of the formulation was investigated. pH values ​​of 3.0, 4.0, 4.5, 5.0, 5.5, and 6.0 were designed, and the formulation was placed at 40°C for 30 days. The results are shown in Tables 6 and 7 below.

[0242] Table 6: pH range study

[0243]

[0244] Table 7: Results of pH Range Study

[0245]

[0246] Note: "ND" means Not Detected.

[0247] The above results indicate that after being placed at 40℃ for 30 days, the pH value of the drug solutions with different pH values ​​did not change significantly, the related substances did not increase significantly, and the total impurities did not differ significantly. The drug solutions were relatively stable within a pH range of 3.0 to 6.0. Therefore, the optimal pH range for the drug solution is 3.0 to 6.0, with 5.5 being the preferred value.

[0248] Example 5: Study on the dosage range of citric acid / sodium citrate

[0249] Based on Example 1, the range of citric acid / sodium citrate dosage was investigated. Samples with different amounts of citric acid / sodium citrate were placed at 40°C for 30 days. The results are shown in Tables 8-9 below.

[0250] Table 8: Study on different citric acid / citric acid dosages

[0251]

[0252] Table 9: Results of the study on citric acid / citric acid dosage

[0253]

[0254] Note: "ND" means Not Detected.

[0255] The above results indicate that increasing the amount of citric acid / sodium citrate did not affect the stability of the formulation. Therefore, the dosage range of citric acid is 0.48~1.2 mg / ml, and the dosage range of sodium citrate is 0.08~0.2 mg / ml.

[0256] Example 6: Study on the concentration of active pharmaceutical ingredient

[0257] Based on Example 1, the dosage range of the active pharmaceutical ingredient was investigated. Samples of 0.5 mg / ml, 5 mg / ml, 10 mg / ml and 25 mg / ml were prepared and placed at 60°C for 10 days. The results are shown in Table 10-11.

[0258] Table 10: Composition of Formulas with Different Active Pharmaceutical Ingredient Contents

[0259]

[0260] Table 11: Results of Illumination Survey

[0261]

[0262] Note: "ND" means Not Detected.

[0263] The above results indicate that there was no significant difference in stability between samples with different active pharmaceutical ingredient (API) concentrations after 10 days at 60℃. The API concentration range was 0.5 mg / ml to 25 mg / ml.

[0264] Example 7 Stability Study

[0265] The stability of formulation 1 at 25℃ was investigated, and the results are shown in Table 12.

[0266] Table 12: Stability Study

[0267]

[0268] The results showed that after being stored at 25°C for 4 months, the pH value, content, and related substances of Formulation 1 did not change significantly, indicating that the formulation was stable.

[0269] Example 8 Pharmacokinetic Study

[0270] This embodiment illustrates that the relative bioavailability of emesitin administered nasally in Beagle dogs is approximately 8 times higher than that administered orally. In a rat model of allergic rhinitis, plasma and local tissue exposures of emesitin administered via nasal drops were significantly higher than those administered orally, and the drug exposure at the target site of the nasal mucosa in the emesitin nasal spray group was approximately 170 times higher than that in the group receiving emesitin fumarate sustained-release capsules orally. Emesitin nasal spray offers clinical advantages such as rapid onset of action, direct action on the nasal mucosa target site, and the potential to improve efficacy and reduce adverse drug reactions.

[0271] The methods for analyzing pharmacokinetic parameters are as follows:

[0272] 1. HPLC analysis conditions are shown in Table 13:

[0273] Table 13: HPLC Analysis Conditions

[0274]

[0275] 2. Mass spectrometry analysis conditions are shown in Table 14:

[0276] Table 14: Mass Spectrometry Analysis Conditions

[0277]

[0278] 3. Linear range of the accompanying standard curve: 0.05000-50.00 ng / mL.

[0279] 4. Pretreatment method: Take 20 μL of plasma sample and place it in a 1.5 mL polyethylene centrifuge tube. Add 20 μL of 50% methanol aqueous solution, then add 20 μL of internal standard working solution (10.00 ng / mL) and 140 μL of 0.1% formic acid methanol solution. Vortex for 30 s, centrifuge at 14000 rpm for 10 min, and take the supernatant and mix it with 0.2% formic acid water (v:v=2:1) ​​before injection for analysis.

[0280] 5. Calculation method of pharmacokinetic parameters: WinNonlin software uses the non-compartmental model method for fitting.

[0281] 8.1 In a Beagle dog pharmacokinetic study, the relative bioavailability (F-relative) of 2 mg emestin administered intranasally in Beagle dogs (approximately 1.7 times the adult oral clinical dose based on animal body surface area) was 8 times that of a single oral administration.

[0282] The main pharmacokinetic parameters AUC0-t, Cmax, and Tmax of Beagle dogs after nasal administration of emesitin nasal spray (formulation 1) and oral administration of emesitin fumarate sustained-release capsules are shown in Table 15. The mean plasma concentration graph and the semi-logarithmic plasma concentration graph are shown in Figure 1.

[0283] Table 15: Summary of major pharmacokinetic parameters (mean ± SD) after nasal administration of emesitine nasal spray and oral administration of emesitine fumarate extended-release capsules in Beagle dogs.

[0284]

[0285] 8.2 In an in vivo pharmacokinetic study of an allergic rhinitis model rat, the relative bioavailability (F-relative) of emestin administered via nasal drops for 7 consecutive days was significantly higher than that of oral administration. The plasma exposure to emestin in rats treated with emestin nasal spray (Formulation 1) was significantly higher than that in rats treated with emestin extended-release fumarate capsules. Furthermore, the exposure to emestin at the target site in the nasal mucosa of the emestin nasal spray group was approximately 65.8–170.5 times higher than that in the emestin extended-release fumarate capsule group. Table 16 details the individual plasma concentrations of emesitin in rats in the emesitin nasal spray group and the emesitin fumarate sustained-release capsule group. Table 17 summarizes the main pharmacokinetic parameters of emesitin in the plasma of rats in the emesitin nasal spray group (the plasma concentrations of emesitin fumarate sustained-release capsule group were mostly below the lower limit of quantitation, so pharmacokinetic parameters could not be calculated). Table 18 details the tissue concentrations of emesitin in rats in the emesitin nasal spray group and the emesitin fumarate sustained-release capsule group.

[0286] Table 16: Individual plasma concentrations of emesitin in rats in the emesitin nasal spray group and the emesitin fumarate sustained-release capsule group.

[0287]

[0288] Table 17: Summary of major pharmacokinetic parameters of emesitin in the plasma of rats in the emesitin nasal spray group ( ±S)

[0289]

[0290] Table 18: Average drug content in rat tissues of rats in the emesitin nasal spray group and the emesitin fumarate sustained-release capsule group.

[0291]

Claims

1. A nasal preparation comprising the following ingredients: Emesine fumarate, 0.01%~5% (w / v%); citric acid, 0.001%~2% (w / v%); sodium citrate, 0.001%~1% (w / v%); disodium edetate, 0.001%~0.1% (w / v%); sodium chloride, 0.65%~0.85% (w / v%); hydroxypropyl methylcellulose, 0.05%~0.20% (w / v%); benzalkonium chloride, 0.001%~0.5% (w / v%); water balance; and pH adjusted to 3.0~6.0 with sodium hydroxide.

2. The nasal preparation according to claim 1, comprising the following components: Emesine fumarate, 0.01%~5% (w / v%); citric acid, 0.001%~2% (w / v%); sodium citrate, 0.001%~1% (w / v%); disodium edetate, 0.001%~0.1% (w / v%); sodium chloride, 0.7%-0.8% (w / v%); hydroxypropyl methylcellulose, 0.05%~0.15% (w / v%); benzalkonium chloride, 0.001%~0.5% (w / v%); water balance; and pH adjusted to 3.0~6.0 with sodium hydroxide.

3. The nasal preparation according to claim 1, comprising the following components: 0.4% (w / v%) emestin fumarate, 0.048% (w / v%) citric acid, 0.008% (w / v%) sodium citrate, 0.01% (w / v%) disodium edetate, 0.75% (w / v%) sodium chloride, 0.1% (w / v%) hydroxypropyl methylcellulose, water balance, and pH adjusted to 5.5 with sodium hydroxide.

4. The nasal preparation according to claim 1, wherein the nasal preparation is a nasal spray.

5. The nasal preparation according to claim 1, wherein it is an aqueous composition.

6. Use of the nasal preparation of any one of claims 1-5 in the preparation of a medicament for treating allergic rhinitis and / or conjunctivitis.

7. The use according to claim 6, wherein the allergic rhinitis includes seasonal allergic rhinitis and perennial allergic rhinitis.

8. A method for preparing a nasal formulation according to any one of claims 1-5, comprising dissolving emestin fumarate and the remaining components of the nasal formulation in water capable of achieving a desired concentration range in the resulting solution.

Citation Information

Patent Citations

  • Emedastine fumarate water-based pharmaceutical composition and preparation method thereof

    CN107875119A

  • Nasal drop

    JP1995215877A